New combo aims to boost Pre-Surgery treatment for stomach cancer
NCT ID NCT07059299
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new combination of the immunotherapy drug tislelizumab plus standard chemotherapy (FLOT) given before surgery for people with stomach, esophageal, or gastroesophageal junction cancer that can be removed. The goal is to see if this longer pre-surgery treatment is safe and works well enough to study further. About 18 adults with locally advanced, resectable cancer will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hämatologisch-Onkologische Praxis Eppendorf (hope)
NOT_YET_RECRUITINGHamburg, 20249, Germany
-
Klinikum rechts der Isar München der TU München
RECRUITINGMünchen, 81675, Germany
-
Krankenhaus Nordwest GmbH Institut für Klinisch-Onkologische Forschung (IKF)
RECRUITINGFrankfurt, 60488, Germany
-
Universitätsklinikum Leipzig
NOT_YET_RECRUITINGLeipzig, 04103, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Could a smartphone program supervised by AI boost recovery after stomach cancer surgery?
- Can a swallowed balloon unlock the genetic secrets of esophageal cancer?